Sucampo Pharmaceuticals, Inc. (SCMP) Receives Average Rating of “Buy” from Brokerages

Shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) have been assigned a consensus rating of “Buy” from the fifteen brokerages that are covering the company, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $20.00.

A number of research analysts recently weighed in on the stock. BidaskClub downgraded shares of Sucampo Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. Zacks Investment Research downgraded shares of Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, February 9th. ValuEngine upgraded shares of Sucampo Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 2nd. Nomura restated a “neutral” rating and set a $18.00 price objective on shares of Sucampo Pharmaceuticals in a research report on Friday, January 26th. Finally, Maxim Group downgraded shares of Sucampo Pharmaceuticals to a “hold” rating in a research report on Monday, January 1st.

Sucampo Pharmaceuticals (SCMP) opened at $18.00 on Wednesday. The stock has a market cap of $849.02, a P/E ratio of -5.47, a PEG ratio of 5.06 and a beta of 1.38. Sucampo Pharmaceuticals has a 52 week low of $9.30 and a 52 week high of $18.75. The company has a quick ratio of 4.46, a current ratio of 5.11 and a debt-to-equity ratio of 7.37.

In other Sucampo Pharmaceuticals news, insider Peter A. Kiener sold 50,000 shares of the company’s stock in a transaction that occurred on Thursday, December 7th. The shares were sold at an average price of $16.50, for a total transaction of $825,000.00. Following the completion of the sale, the insider now directly owns 52,023 shares of the company’s stock, valued at $858,379.50. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 4.13% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently made changes to their positions in the business. The Manufacturers Life Insurance Company increased its holdings in Sucampo Pharmaceuticals by 4.1% during the second quarter. The Manufacturers Life Insurance Company now owns 19,983 shares of the biopharmaceutical company’s stock valued at $209,000 after buying an additional 790 shares during the last quarter. Thrivent Financial For Lutherans increased its holdings in Sucampo Pharmaceuticals by 11.3% during the second quarter. Thrivent Financial For Lutherans now owns 15,270 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 1,550 shares during the last quarter. Ameriprise Financial Inc. increased its holdings in Sucampo Pharmaceuticals by 1.3% during the second quarter. Ameriprise Financial Inc. now owns 131,790 shares of the biopharmaceutical company’s stock valued at $1,384,000 after buying an additional 1,690 shares during the last quarter. Teachers Advisors LLC increased its holdings in Sucampo Pharmaceuticals by 2.9% during the second quarter. Teachers Advisors LLC now owns 68,499 shares of the biopharmaceutical company’s stock valued at $719,000 after buying an additional 1,953 shares during the last quarter. Finally, Voya Investment Management LLC increased its stake in shares of Sucampo Pharmaceuticals by 22.7% in the second quarter. Voya Investment Management LLC now owns 13,411 shares of the biopharmaceutical company’s stock worth $141,000 after purchasing an additional 2,477 shares in the last quarter. 67.09% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This piece was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/02/14/sucampo-pharmaceuticals-inc-scmp-receives-average-rating-of-buy-from-brokerages.html.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Analyst Recommendations for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply